RBPMS2, as a novel biomarker for predicting lymph node metastasis, guides therapeutic regimens in gastric cancer.

RNA-binding protein with multiple splicing 2 (RBPMS2) is a critical gene that encodes a member of the RNA-recognition-motif-containing protein family and is involved in the development and dedifferentiation of digestive smooth muscle cells. However, whether RBPMS2 has an effect on the prognosis of gastric cancer (GC) and its possible mechanism during GC progression remain unknown. Here, we collected 596 GC patients who underwent curative surgical resection to evaluate expression of RBPMS2. RBPMS2 was upregulated in GC tissues, and was associated with lymph node metastasis. We analysis the KEGG pathway and GO biological processes, cellular component and molecular function of RBPMS2 interactive genes, as well as RBPMS2-binding partner ESRP1 interactive genes. We also focus on the correlation analysis between EMT-related genes and RBPMS2/ESRP1. Finally, we analysed the correlation between RBPMS2 expression and chemotherapeutic drugs which may assist in GC therapy and demonstrated that RBPMS2 expression was associated with tumour mutation burden (TMB) and Microsatellite Instability (MSI), as well as immune infiltration level in GC.